ClinicalTrials.gg

Program

Anti-c-Met/MMAE ADC RC108

Its studies are mostly in Gastrointestinal Neoplasms · Carcinoma, Non-Small-Cell Lung, led by RemeGen.

Furthest: phase 2, since Nov 17, 20224 company-led studies, 2 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
RemeGen42 open or runningphase 2since Nov 17, 2022Oct 30, 2020none ahead

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Oct 30, 2020First study: phase 1 study in Solid TumorFirst studyNCT04617314 · 67 enrolled · China
  2. Nov 17, 2022Phase 2 study in Gastrointestinal NeoplasmsNCT05628857 · 29 enrolled · China
  3. Mar 13, 2023Phase 2 study in NSCLCNCT05821933 · 106 planned · China
  4. Apr 30, 2025Phase 2 study in Carcinoma, Non-Small-Cell LungNCT06962865 · 80 planned · China

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 4 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06962865Carcinoma, Non-Small-Cell Lung · China2RecruitingMay 31, 202680
NCT05821933NSCLC · China2RecruitingSep 1, 2025106
NCT05628857Gastrointestinal Neoplasms · China2CompletedDec 31, 202529
NCT04617314Solid Tumor · China1CompletedDec 31, 202567

How it is read

Names in the registry

  • “RC108”, 4 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.